<DOC>
	<DOCNO>NCT02188719</DOCNO>
	<brief_summary>The purpose study look safety : - Taking specific combination immunosuppressant drug liver transplantation - Receiving one three different dos donor-alloantigen-reactive regulatory T cell ( darTregs ) take specific combination drug</brief_summary>
	<brief_title>Donor-Alloantigen-Reactive Regulatory T Cell ( darTregs ) Liver Transplantation</brief_title>
	<detailed_description>After liver transplantation , immunosuppressant must take every day prevent body injure transplant liver process call rejection . People take drug may experience side effect . Studies show body 's cell , call T regulatory cell ( Tregs ) , may play part accept transplant liver . The investigator learn whether scientist take Tregs blood liver transplant recipient teach protect transplant liver rejection . In laboratory , recipient Tregs expose cell liver donor . Research data suggest give `` donor reactive '' Tregs back transplant recipient might allow liver transplant recipient take low dos immunosuppressant , perhaps stop altogether , without reject liver .</detailed_description>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Subjects meet follow criterion eligible enrollment study participant : Able understand provide inform consent Endstage liver disease list primary solitary liver transplant Have calculate Model End Stage Liver Disease ( MELD ) score ≤ 25 time study entry/consent Female male subject reproductive potential must agree use effective method birth control duration study . If history HCV , complete current treatment HCV AND detectable HCV RNA . Subjects HCC meeting Milan criterion . Below exclusion criterion assess study enrollment , prior Stage 1 study procedure . Subjects meet criterion eligible Stage 1 study procedure . Note subject Cohort 1a 1b NOT undergo leukapheresis regardless eligibility . End stage liver disease secondary autoimmune etiology ( autoimmune hepatitis , primary biliary cirrhosis , primary sclerosing cholangitis ) International Normalized Ratio ( INR ) &gt; 2.0 History less 5 year remission malignancy , except 1 ) HCC 2 ) history adequately treat insitu cervical carcinoma , adequately treat basal squamous cell carcinoma skin . History previous organ , tissue cell transplant Serologic evidence human immunodeficiency ( HIV ) 1 2 infection EpsteinBarr Virus ( EBV ) cytomegalovirus ( CMV ) seronegativity ( EBV CMV naïve candidate ) Chronic use systemic glucocorticoid Immunosuppression ( IS ) , biologic immunomodulators Chronic condition require anticoagulation liver transplantation Any chronic illness prior treatment , opinion investigator , precludes study participation Participation study involve investigational drug regimen precede year Hemoglobin &lt; 9.0 g/dL within 10 day prior screen Neutrophils &lt; 1,500/μL within 10 day prior screen Platelets &lt; 40,000/μL within 10 day prior screen Thymoglobulin Exclusion Criteria B ( Stage 2 ) : Below exclusion criterion assess prior administration Thymoglobulin® . Subjects meet criterion receive Thymoglobulin® : Calculated Model End Stage Liver Disease ( MELD ) score &gt; /= 25 time decease donor liver transplant Last alphafetoprotein ( AFP ) obtain prior liver transplantation &gt; 400 μg/L candidate Hepatocellular Carcinoma ( HCC ) Unacceptable leukapheresis product participant enrol Cohorts 2 , 3 , 4 per UCSF HICTF manufacturing specification Absence donor spleen lymphocytes participant Human leukocyte antigen ( HLA ) DR ( DR one class II antigens ) match donor locus Subject &lt; 21 &gt; 70 year age time transplantation Located intensive care unit 72 hour transplantation Hemoglobin &lt; 8.0 g/dL Absolute neutrophil count &lt; 1,200/μL Platelets &lt; 40,000/μL Positive pregnancy test females child bear potential Unexpected histopathology back table liver biopsy contraindicate initiation Treg supportive IS regimen . Development condition require chronic anticoagulation . Hypersensitivity rabbit proteins excipient Thymoglobulin® . Detectable HCV RNA less six month end treatment HCV time transplantation ( i.e. , meet criterion SVR ) . Below exclusion criterion assess prior conversion Everolimus ( EVR ) base IS regimen . ( Assessed day 3044 transplantation continuation trial ) All subject regardless eligibility EVR conversion , follow receive darTregs move safety follow : Explanted liver evidence increase risk recurrent cancer risk ( hepatocellular ( HCC ) tumor burden exceed Milan criterion ; presence vascular invasion ; cholangiocarcinoma morphology ) Insufficient depletion recipient T cell , define nadir CD3 count ≥50 cell μ/L ( 50 cell /mcL ) total lymphocyte count ≥ 0.1x 109/L CD3 count unavailable Development condition require chronic anticoagulation . Clinical evidence biliary obstruction Alanine Aminotransferase ( ALT ) &gt; 2.0 x upper limit normal ( ULN ) Inability taper corticosteroid 44 day ( +/ 2 day ) transplant Detectable circulate HCV RNA . Everolimus Conversion Criteria C2 ( assess prior conversion EVR base IS regimen ; EVR initiate prior 30 day liver transplantation ) . Subjects follow remain TACbased IS regimen . Evidence hepatic artery stenosis thrombosis Doppler examination angiography within 7 day prior conversion Urine protein/creatinine ratio &gt; 1.0 within 7 day prior conversion Calculated GFR le 30 ml/min per MDRD4 equation within 7 day prior conversion Physical examination documentation abnormal wound heal uncontrolled wound infection Hemoglobin &lt; 8.0 g/dL within 7 day prior conversion Absolute neutrophil count &lt; 1,200/μL within 7 day prior conversion Platelets &lt; 50,000/μL within 7 day prior conversion *Below exclusion criterion assess prior darTreg infusion subject Cohorts 2 , 3 , 4 . Subjects Cohort 2 , 3 , 4 meet criterion receive darTreginfusion : Inability unwillingness participant give additional write informed consent Unacceptable darTreg product Detectible circulate EpsteinBarr Virus ( EBV ) cytomegalovirus ( CMV ) DNA within 10 day prior darTreg infusion Detectible HBV DNA within 10 day prior darTreg infusion Detectable circulate HCV RNA within 10 day prior darTreg infusion . Alanine Aminotransferase ( ALT ) &gt; 1.5x upper limit normal within 10 day darTreg infusion Most recent , great 10 day prior darTreg infusion,12 hour TAC trough level &gt; 8 μg/L subject Most recent , great 10 day prior darTreg infusion,12 hour EVR trough level &lt; 5 μg/L subject EVR For subject EVRbased IS , receive Mycophenolate Mofetil ( MMF ) within 10 day prior darTreg infusion Evidence acute rejection chronic rejection accord Banff criterion protocol allograft biopsy base local assessment Received vaccination within 14 day prior darTreg infusion Positive pregnancy test females child bear potential Inability unwillingness participant comply study protocol procedure . Calculated glomerular filtration rate ( eGFR ) less 40 ml/min per MDRD4 equation within 7 day prior infusion .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Donor-Alloantigen-Reactive Regulatory T Cell Therapy</keyword>
	<keyword>Tregs</keyword>
	<keyword>Cell- Tissue-Based Therapy</keyword>
	<keyword>Immunotherapy , Adoptive</keyword>
	<keyword>Liver Transplantation</keyword>
</DOC>